Progress and challenges in the use of Cofilin-1 as a prognostic and predictive biomarker for cancer management.
1/5 보강
Cofilin-1 (CFL1) is an actin-regulating protein encoded by the CFL1 gene and plays a central role in cytoskeletal dynamics, cell motility, and invasion-processes critical for tumor progression and met
APA
Branco MA, Kunst BM, et al. (2025). Progress and challenges in the use of Cofilin-1 as a prognostic and predictive biomarker for cancer management.. Gene, 968, 149746. https://doi.org/10.1016/j.gene.2025.149746
MLA
Branco MA, et al.. "Progress and challenges in the use of Cofilin-1 as a prognostic and predictive biomarker for cancer management.." Gene, vol. 968, 2025, pp. 149746.
PMID
40902692 ↗
Abstract 한글 요약
Cofilin-1 (CFL1) is an actin-regulating protein encoded by the CFL1 gene and plays a central role in cytoskeletal dynamics, cell motility, and invasion-processes critical for tumor progression and metastasis. Aberrant CFL1 expression has been linked to poor prognosis, therapeutic resistance, and increased metastatic potential across several human cancers. This review consolidates clinical evidence from studies involving human samples over the past 15 years, highlighting CFL1 as a candidate prognostic and predictive biomarker. We analyze tumor-specific expression patterns, detection methodologies as immunohistochemistry, ELISA, proteomics and discuss regulatory pathways involving CFL1. Particular attention is given to prostate cancer, where the lack of reliable molecular biomarkers for risk stratification represents a clinical gap. Despite promising associations, the clinical translation of CFL1 is hindered by heterogeneity in quantification protocols and limited prospective validation. We outline the key challenges and propose future directions to establish CFL1 as a clinically actionable biomarker, with potential relevance to personalized cancer management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.